CymaBay Therapeutics, Inc. (CBAY) Stock

About CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.

CymaBay Therapeutics, Inc. is headquartered in US.

CymaBay Therapeutics, Inc. (CBAY) stock trades at $32.48 with a market capitalization of $3.73B. The stock is valued at a price-to-earnings (P/E) ratio of -32.81, price-to-book of 11.80, price-to-sales of 119.98. Over the past 52 weeks the stock has ranged between $7.26 and $32.50, and currently trades at its 52-week high.

On profitability, CymaBay Therapeutics, Inc. generates a return on equity (ROE) of -64.17%, return on capital employed of -25.56%, an operating margin of -327.23%, a net profit margin of -339.10%.

Official website: www.cymabay.com